Atlas Arteria (ALX)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 3.700 |
|---|---|
| 52-week range | 3.580 – 5.235 |
| Return, 1 month / 3 months | −11.1% / −23.4% |
| Return, 1 year / 3 years | −19.3% / −10.8% |
| Trend | Below its 200-day average |
| RSI (14) | 33 |
| Volatility (1 year) | 21.8% |
| Worst drawdown (1 year) | -24.7% |
| Average daily value traded | 11.80M AUD |
| Dividend yield | 10.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Atlas Arteria is an Australian infrastructure company that invests in and operates toll roads. Its main asset is a stake in a motorway network in France, and it also holds interests in toll roads in the United States and Germany. The company earns revenue from tolls paid by motorists and freight operators using these roads, and it is based in Australia while managing a portfolio of road concessions across several countries.
The shares are listed on the Australian Securities Exchange in Australia under the code ALX, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Atlas Arteria (ALX) trades on the Australian Securities Exchange in Australia. It last closed at AUD 3.700 on 23 October 2026.
Its price-based Market X-Ray is 70 out of 100 (a fair price profile), ranking 383 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 19.3% and over the last three months it fell 23.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 57 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -16.4% | ||
| From 52-week high | -27.7% | ||
| Momentum | 47 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -23.4% | ||
| 6-month return | -9.5% | ||
| 12-month return, skipping the last month | -9.2% | ||
| Stability (higher is calmer) | 90 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 21.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.7% | ||
| Liquidity | 93 · Strong | Trades actively. | |
| Average daily value traded | 11.80M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 73 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 10.8% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −2.4% |
|---|---|
| 1 month | −11.1% |
| 3 months | −23.4% |
| 6 months | −9.5% |
| 1 year | −19.3% |
| 3 years | −10.8% |
| 5 years | −10.7% |
Signals
| 50-day / 200-day average | 4.133 / 4.424 |
|---|---|
| Golden / death cross (60 days) | Death, 17 days ago |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.111 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 23 Sep 2026 | AUD 0.2000 |
| 25 Mar 2026 | AUD 0.2000 |
| 24 Sep 2025 | AUD 0.2000 |
| 25 Mar 2025 | AUD 0.2000 |
| 24 Sep 2024 | AUD 0.2000 |
| 26 Mar 2024 | AUD 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.